Current Approaches in Dendritic Cell Generation and Future Implications for Cancer Immunotherapy

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2007 May 16

PMID 17503040

Citations 66

Authors

Sandra Tuyaerts

Joeri L Aerts

Jurgen Corthals

Bart Neyns

Carlo Heirman

Karine Breckpot

Kris Thielemans

Aude Bonehill

Affiliations

Soon will be listed here.

Abstract

The discovery of tumor-associated antigens, which are either selectively or preferentially expressed by tumors, together with an improved insight in dendritic cell biology illustrating their key function in the immune system, have provided a rationale to initiate dendritic cell-based cancer immunotherapy trials. Nevertheless, dendritic cell vaccination is in an early stage, as methods for preparing tumor antigen presenting dendritic cells and improving their immunostimulatory function are continuously being optimized. In addition, recent improvements in immunomonitoring have emphasized the need for careful design of this part of the trials. Still, valuable proofs-of-principle have been obtained, which favor the use of dendritic cells in subsequent, more standardized clinical trials. Here, we review the recent developments in clinical DC generation, antigen loading methods and immunomonitoring approaches for DC-based trials.

Citing Articles

Current and Future Trends of Colorectal Cancer Treatment: Exploring Advances in Immunotherapy.

Nikolouzakis T, Chrysos E, Docea A, Fragkiadaki P, Souglakos J, Tsiaoussis J Cancers (Basel). 2024; 16(11).

PMID: 38893120 PMC: 11171065. DOI: 10.3390/cancers16111995.

Colorectal Cancer Immunotherapy: State of the Art and Future Directions.

Cornista A, Giolito M, Baker K, Hazime H, Dufait I, Datta J Gastro Hep Adv. 2023; 2(8):1103-1119.

PMID: 38098742 PMC: 10721132. DOI: 10.1016/j.gastha.2023.09.007.

Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer.

Liu D, Che X, Wang X, Ma C, Wu G Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895855 PMC: 10610367. DOI: 10.3390/ph16101384.

Adjuvant dendritic cell-based immunotherapy after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with malignant peritoneal mesothelioma: a phase II clinical trial.

Dietz M, Quintelier K, van Kooten J, de Boer N, Vink M, Brandt-Kerkhof A J Immunother Cancer. 2023; 11(8).

PMID: 37536940 PMC: 10401259. DOI: 10.1136/jitc-2023-007070.

COVID-19 immunotherapy: Treatment based on the immune cell-mediated approaches.

Zavvar M, Yahyapoor A, Baghdadi H, Zargaran S, Assadiasl S, Abdolmohammadi K Int Immunopharmacol. 2022; 107:108655.

PMID: 35248946 PMC: 8872837. DOI: 10.1016/j.intimp.2022.108655.

References

Nair S, Morse M, Boczkowski D, Cumming R, Vasovic L, Gilboa E . Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg. 2002; 235(4):540-9. PMC: 1422470. DOI: 10.1097/00000658-200204000-00013. View

Koido S, Nikrui N, Ohana M, Xia J, Tanaka Y, Liu C . Assessment of fusion cells from patient-derived ovarian carcinoma cells and dendritic cells as a vaccine for clinical use. Gynecol Oncol. 2005; 99(2):462-71. DOI: 10.1016/j.ygyno.2005.07.019. View

Ten Brinke A, Karsten M, Dieker M, Zwaginga J, Vrielink H, van Ham S . Generation of dendritic cells for immunotherapy is minimally impaired by granulocytes in the monocyte preparation. Immunobiology. 2006; 211(6-8):633-40. DOI: 10.1016/j.imbio.2006.05.012. View

Luft T, Pang K, Thomas E, Bradley C, Savoia H, Trapani J . A serum-free culture model for studying the differentiation of human dendritic cells from adult CD34+ progenitor cells. Exp Hematol. 1998; 26(6):489-500. View

Santini S, Lapenta C, Logozzi M, Parlato S, Spada M, Di Pucchio T . Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J Exp Med. 2000; 191(10):1777-88. PMC: 2193160. DOI: 10.1084/jem.191.10.1777. View

Renneson J, Salio M, Mazouz N, Goldman M, Marchant A, Cerundolo V . Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells. Clin Exp Immunol. 2005; 139(3):468-75. PMC: 1809309. DOI: 10.1111/j.1365-2249.2005.02700.x. View

Nowrousian M, Waschke S, Bojko P, Welt A, Schuett P, Ebeling P . Impact of chemotherapy regimen and hematopoietic growth factor on mobilization and collection of peripheral blood stem cells in cancer patients. Ann Oncol. 2003; 14 Suppl 1:i29-36. DOI: 10.1093/annonc/mdg706. View

Jonuleit H, Tuting T, Stuge T, Paragnik L, Kandemir A, Lee P . A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001; 93(2):243-51. DOI: 10.1002/ijc.1323. View

Franzke A . The role of G-CSF in adaptive immunity. Cytokine Growth Factor Rev. 2006; 17(4):235-44. DOI: 10.1016/j.cytogfr.2006.05.002. View

10.

Berger T, Feuerstein B, Strasser E, Hirsch U, Schreiner D, Schuler G . Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002; 268(2):131-40. DOI: 10.1016/s0022-1759(02)00189-8. View

11.

Breckpot K, Corthals J, Heirman C, Bonehill A, Michiels A, Tuyaerts S . Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. Hum Gene Ther. 2004; 15(6):562-73. DOI: 10.1089/104303404323142015. View

12.

Adams M, Navabi H, Jasani B, Man S, Fiander A, Evans A . Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine. 2003; 21(7-8):787-90. DOI: 10.1016/s0264-410x(02)00599-6. View

13.

Orsini E, Pasquale A, Maggio R, Calabrese E, Mauro F, Giammartini E . Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. Br J Haematol. 2004; 125(6):720-8. DOI: 10.1111/j.1365-2141.2004.04971.x. View

14.

Figdor C, de Vries I, Lesterhuis W, Melief C . Dendritic cell immunotherapy: mapping the way. Nat Med. 2004; 10(5):475-80. DOI: 10.1038/nm1039. View

15.

Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A . A clinical development paradigm for cancer vaccines and related biologics. J Immunother. 2007; 30(1):1-15. DOI: 10.1097/01.cji.0000211341.88835.ae. View

16.

Vanderlugt C, Miller S . Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol. 2002; 2(2):85-95. DOI: 10.1038/nri724. View

17.

Rosenberg S, Yang J, Restifo N . Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004; 10(9):909-15. PMC: 1435696. DOI: 10.1038/nm1100. View

18.

Chen B, Stiff P, Sloan G, Kash J, Manjunath R, Pathasarathy M . Replicative response, immunophenotype, and functional activity of monocyte-derived versus CD34(+)-derived dendritic cells following exposure to various expansion and maturational stimuli. Clin Immunol. 2001; 98(2):280-92. DOI: 10.1006/clim.2000.4968. View

19.

Zwaveling S, Ferreira Mota S, Nouta J, Johnson M, Lipford G, Offringa R . Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol. 2002; 169(1):350-8. DOI: 10.4049/jimmunol.169.1.350. View

20.

Osugi Y, Vuckovic S, Hart D . Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood. 2002; 100(8):2858-66. DOI: 10.1182/blood.V100.8.2858. View